ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aminolevulinic Acid

Also written as “Aminolevulinic Acid (ALA)”, “5 Aminolevulinic Acid” and “PD P 506 A”.

Its studies are mostly in Keratosis, Actinic · Glioma · Glioblastoma · Breast Neoplasms · Malaria, led by 10 companies.

Drug pageAminolevulinic Acid: every studyMany companies study it; this page follows only the 22 they lead. All 114 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 7, 201422 company-led studies, 3 open or runningNext primary completion: Oct 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sun Pharmaceutical Industriesits history only100 open or runningphase 3since May 7, 2014Jun 24, 2008none ahead
Alpheus Medicalits history only21 open or runningphase 1since May 2, 2022May 2, 2022Oct 30, 2027phase 1 · NCT07862647
medacits history only20 open or runningphase 3since Oct 18, 2005Oct 18, 2005none ahead
photonamic GmbH & Co. KGits history only20 open or runningphase 2since Jul 11, 2018Jul 11, 2018none ahead
Hemerion Therapeutics11 open or runningphase 2since Feb 8, 2023Feb 8, 2023none ahead
Lee's Pharmaceuticalits history only11 open or runningphase 3since Nov 27, 2023Nov 27, 2023Dec 2027phase 3 · NCT06160492
Neopharma Japanits history only10 open or runningphase 2since Jul 12, 2019Jul 12, 2019none ahead
Nobelpharmaits history only10 open or runningphase 3since Jul 16, 2010Jul 16, 2010none ahead
SBI ALApharma Canadaits history only10 open or runningphase 3since Mar 22, 2021Mar 22, 2021none ahead
Shanghai Fudan-Zhangjiang Bio-Pharmaceuticalits history only10 open or runningphase 3since May 12, 2024May 12, 2024none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hemerion Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2015Named aminolevulinic acidINNProposed as its International Nonproprietary Name in WHO's List 114
  2. Feb 8, 2023First study: phase 2 study in GliomaFirst studyNCT05736406 · 12 enrolled · United States, France

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Hemerion Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05736406Glioma · United States, France2Active, not recruitingMar 6, 202612

How it is read

Names in the registry

  • “Aminolevulinic Acid (ALA)”, 3 entries
  • “5 Aminolevulinic Acid”, 2 entries
  • “PD P 506 A”, 2 entries
  • “Aminolevulinic Acid”, 2 entries
  • “ALA”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.